September 03, 2020

Managing Consolidated Trial Risk in Drug and Device Litigation

Product liability and mass torts partners Tarifa Laddon and Patrick Reilly, with associate Theodore O’Reilly, co-authored an article for For the Defense titled “Managing Consolidated Trial Risk in Drug and Device Litigation.”

The authors assert that, in the current environment, consolidated, multi-plaintiff trials seem to be an inherent risk — an important source of leverage for plaintiffs’ counsel. For this reason, defense counsel may sometimes find themselves resigned to the possibility that trial could involve a multi-plaintiff cacophony with a potentially outsized verdict from a confused jury. But if consolidated trials mean leverage for plaintiffs in mass tort drug and device litigation, that means single plaintiff trials are leverage for defendants. The authors offer a few guiding principles for defense-side litigators that consider how individual cases affect each other and can be leveraged from the outset of mass tort litigation.


The Faegre Baker Daniels website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Baker Daniels' cookies information for more details.